Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Serum Albumin in Mild-to-moderate Alzheimer's Disease
NCT06489015Phase 1Completed
- Sponsor
- Protogen
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant human serum albumin in Alzheimer's disease (AD) (3 arms), sponsored by Protogen. Primary endpoint: Adverse Events at 41 weeks. Started Aug 2024; status: completed.
02
Drugs
recombinant human serum albumin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06489015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489015.